Decoding lung health thru Aerosol Biopsy
by Deton Corp. on March 5th, 2018

​March 5, 2018 - We are thrilled! Out of 13 companies that pitched at UCLA, Deton was chosen as the Winner of the Audience Choice Award. The audience included judges from Illumina Ventures, Johnson & Johnson, Becton Dickinson, Amgen, W.L. Gore, Bristol Capital Advisors, venture capital firms, and local angel groups. Deton advanced to the main event through a 1 min elevator pitch. During the  5 min pitch followed by a Q & A Deton convinced the judges and audience to go on and win the Audience Choice Award. More than 70 companies were screened to be part of the 2018 Medtech Innovator Los Angeles Pitch Event and more than 700 companies applied to be part of the Medtech Innovator’s global competition and accelerator program.
 
About Deton
Deton is decoding lung health using our Aerosol Biopsy solution. Our mission is to transform the understanding of lung disease by providing complete and timely information for treatment decisions as well as research and therapeutics development. Our Aerosol Biopsy solution captures aerosol droplets that originate in the lungs and are expelled during cough and then extracts the genetic information contained within them. Unlike current methods, the Aerosol Biopsy method is non-invasive, accurate and reliable.
 
About MedTech Innovator
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. MedTech Innovator’s mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.
 
To learn more about MedTech Innovator, visit https://medtechinnovator.org/ and follow@MedTechAwards on Twitter.
 

by Deton Corp. on July 20th, 2017

​Deton Corp. has been awarded a $225,000 National Institute of Health (NIH) Small Business Innovation Research (SBIR) contract. The award will fund a clinical study to investigate the advantages of using the Deton Cough Collector for pediatric Cystic Fibrosis patients with lower respiratory infections.

by Deton Corp. on March 22nd, 2017

​Most Promising Company at the 2017 Molecular Medicine Tri-Conference
​On February 22, 2017, Deton CEO and Co-Founder Patrick Sislian, PhD took 1st place at the 2017 Molecular Medicine Tri-Conference “Swimming with the Sharks” competition in San Francisco.  Deton was chosen as the Most Promising Company by a panel of judges consisting of venture capitalists, angels, and diagnostic industry executives. The judges noted that Deton had a well thought out go-to-market strategy, a unique solution addressed a large unmet clinical need, and a clear ask.  “We at Deton are incredibly excited and grateful for this diagnostic industry award,” said Sislian. “The future of medicine is increasingly evidence-based and our win shows the the Cough Collector is well positioned to enable lower respiratory disease diagnosis.”

Deton presented as one of the 8 finalists selected from numerous applicants to this year’s competition from across molecular medicine, including drug discovery, genomics, diagnostics and information technology.  The other finalists were: Abreos Biosciences, Envision Genomics, Nephrogen Sciences, Selfdiagnostics, Geneoscopy, PrecisionProfile, SpinDiag. 
About Molecular Medicine Tri-Conference
Attracting over 3,500 drug discovery and development professionals from over 40 countries in 2016, the Molecular Medicine Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology.  This conference features over 500 speakers from across all industries and research fields across the world as well as over 400 presentations and panel discussions, 30 roundtable discussions and over 200 companies exhibiting.  Back by popular demand is the "Swimming with the Sharks" competition.  Companies seeking venture funding will pitch their company's value proposition to a panel of judges and the top place winner will receive recognition as the "2017 Tri-Con Most Promising Company".

About Deton
Deton is promoting lung health by enabling diagnosis of disease through the collection, management, and analysis of cough aerosols. Deton’s solution, the Cough Collector, will make diagnosing lower respiratory infections easy, rapid and reliable, paving the way for targeted treatments and better patient outcomes. Armed with the evidence, doctors will be able to prescribe antibiotics empowered with reliable information. Deton is headquartered in Pasadena, California (Los Angeles). For more information, please visit www.detoncorp.com 

by Deton Corp. on October 1st, 2016

Deton has been selected by the National Institutes of Health to be featured at the AdvaMed2016 Innovation Showcase in Minneapolis. As part of the Infectious Disease Management panel, Patrick Sislian will share his insights on the challenges of lower respiratory infection diagnostics and the effective collection of samples through aerosols produced by cough.  The moderated panel will take place on October 17 at 4:40pm. 

by Deton Corp. on August 18th, 2016

​Deton was selected, as one of seven medical device companies, to participate in the Innovation Challenge at the 10th RESI Conference in Boston on September 13, 2016. If you are attending, swing by our booth to meet our CEO, Patrick Sislian, and our CSO, David Aloisi, and learn more about the Cough Collector, a device that will make diagnosing lower respiratory infections easy and reliable.